

Cemiplimab

Catalogue No.: abx831484

Cemiplimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD1/CD279, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Cemiplimab is a fully human PD-1 antibody. The first indication for the marketing application is metastatic/locally advanced cutaneous squamous cell carcinoma (Cutaneous Squamous Cell Carcinoma, CSCC). It is an intravenous immunotherapy targeting the PD-1 pathway, which can help the immune system fight cancer cells.

Target:	PDCD1/PD1/CD279
Clonality:	Monoclonal
Reactivity:	Human
Expression:	Recombinant
Tested Applications:	ELISA, WB
Host:	Human
Recommended dilutions:	Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
Isotype:	IgG4 Kappa
Form:	Liquid
Purity:	> 95%
Purification:	Purified from cell culture supernatants by Protein A/G chromatography.
Storage:	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer:	0.01 M PBS. pH 7.4.
CAS Number:	1801342-60-8
Concentration:	Batch-dependent, typically between 0.5-2.0 mg/ml.
Note:	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.